About Service

Make Lives Better

A rapid-acting, novel treatment for adults with Treatment-Resistant Depression (TRD). It is administered as a nasal spray in a supervised clinical setting, offering relief when standard oral antidepressants have failed.

Who needs it?

Adults diagnosed with Major Depressive Disorder (MDD) who have not responded adequately to two or more different antidepressant medications taken for a sufficient duration at therapeutic doses. It is for those with Treatment-Resistant Depression.
Major Depressive Disorder (MDD)
Two or more
Treatment-Resistant Depression.

Step-by-Step Support

How we provide the service

Learn how our structured, personalized process guides each individual through assessment, planning, and tailored support to achieve meaningful results.
01
Supervised Administration
Treatment involves supervised administration in our clinic under the care of a psychiatrist. The patient is monitored for at least two hours after administration.
02
Combined Medication Requirement
Esketamine must be taken concurrently with an oral antidepressant.
03
Safe Observation Environment
We provide a calm, safe environment for the required observation period.

Specific FAQs

1. Is this the same as Ketamine?

Esketamine is a specific formulation (S-enantiomer) of Ketamine, approved for TRD and administered via a regulated nasal spray.

Some patients report symptom improvement within 24-48 hours, which is typically faster than traditional antidepressants

Common temporary side effects include dissociation, dizziness, and nausea, which is why supervision is required.